MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, SMTI made $26,333,819 in revenue. -$30,411,153 in net income. Net profit margin of -115.48%.

Income Overview

Revenue
$26,333,819
Net Income
-$30,411,153
Net Profit Margin
-115.48%
EPS
-$3.4
Unit: Dollar
Revenue Breakdown
    • Soft Tissue Repair Products
    • Bone Fusion Products
Revenue Breakdown
    • Selling, general and administrat...
    • Total other income (expense)
    • Cost of goods sold
    • Others

Unit: Dollar
Income Statement
2025-09-30
2025-06-30
2025-03-31
2024-12-31
Net revenue
26,333,819 25,830,834 23,434,096 22,421,001.5
Cost of goods sold
1,874,214 1,937,282 1,834,967 2,069,614
Gross profit
24,459,605 23,893,552 21,599,129 20,351,387.5
Selling, general and administrative
19,877,875 21,553,194 21,440,610 19,304,500
Research and development
1,029,591 1,257,475 1,114,138 1,679,090.5
Depreciation and amortization
610,899 1,114,231 1,124,410 1,356,931.5
Change in fair value of earnout liabilities
-0 -1,035,839
Total operating expenses
21,518,365 23,924,900 23,679,158 21,304,683
Operating income (loss)
2,941,240 -31,348 -2,080,029 -953,295.5
Interest income
-0 3,672 5,494.5
Interest expense
1,818,105 1,791,568 1,317,092 778,236
Share of losses from equity method investments
-288,642 -195,482 -143,608 -19,519.667
Gain on disposal of property and equipment
-0 9,674 -
Total other income (expense)
2,106,747 -1,987,050 -1,447,354 -796,526.5
Net income (loss) from continuing operations
834,493 ---
Net loss from discontinued operations (including asset impairment charge of 26,472,407 in 2025) (note 3)
-31,246,601 ---
Net loss
-30,412,108 -2,018,398 -3,527,383 -1,749,822
Net loss attributable to noncontrolling interest from continuing operations
-955 ---
Less total net loss attributable to noncontrolling interest
-955 -4,036 -206 -98,439.5
Net loss attributable to sanara medtech shareholders
-30,411,153 -2,014,362 -3,527,177 -1,651,382.5
Net income (loss) per share of common stock, basic
-3.52 -0.23 -0.41 -0.195
Net income (loss) per share of common stock, diluted
-3.4 -0.23 -0.41 -0.195
Weighted average number of common shares outstanding, basic
8,646,668 8,612,986 8,570,104 -4,250,996
Weighted average number of common shares outstanding, diluted
8,940,734 8,612,986 8,570,104 -4,250,996
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Bone Fusion Products$2,909,693 Soft Tissue RepairProducts$23,424,126 Net revenue$26,333,819 Net lossattributable to...-$955 something is missing$4,213,494 Gross profit$24,459,605 Cost of goods sold$1,874,214 Net lossattributable to sanara...-$30,411,153 Less total net lossattributable to...-$955 Total other income(expense)$2,106,747 Operating income (loss)$2,941,240 Share of losses fromequity method...-$288,642 Interest expense$1,818,105 Total operatingexpenses$21,518,365 Net loss-$30,412,108 Net income (loss)from continuing...$834,493 something is missing-$4,213,494 Depreciation andamortization$610,899 Research and development$1,029,591 Selling, general andadministrative$19,877,875 Net loss fromdiscontinued operations...-$31,246,601

Sanara MedTech Inc. (SMTI)

Sanara MedTech Inc. (SMTI)